Developer docs
API playgroundTry for free, no card

Search company profiles

Nonagen Bioscience

Full company profile

uuid000dsz4

Namestring
Nonagen Bioscience
Legal namestring
Nonagen Bioscience Corporation
Websiteurl
nonagen.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Nonagen Bioscience Corporation is a clinical-stage diagnostics company developing the Oncuria multiplex protein immunoassay platform for bladder cancer detection, recurrence monitoring, and treatment response prediction. The company serves urologists and clinics evaluating patients presenting with hematuria (blood in urine), patients under surveillance for prior bladder cancer, and patients with non-muscle invasive bladder cancer being considered for BCG therapy. Headquartered in Irvine, California, Nonagen operates its own CAP-accredited, CLIA-certified clinical laboratory (CLIA 05D2051927, CAP 8862074) where it processes specimens shipped from healthcare providers, supported by California and Rhode Island state certifications.

The Oncuria platform is built on xMAP Luminex multiplex bead-based immunoassay technology, quantifying 10 proprietary protein biomarkers (APOE, A1AT, ANG, CA9, IL8, MMP9, MMP10, PAI1, SDC1, and VEGF) from a single voided urine sample using as little as 150 microliters in under 5 hours. A proprietary multivariate classifier algorithm combines biomarker concentrations and clinical inputs into a single risk score delivered via HIPAA-compliant cloud infrastructure. The marketed suite includes Oncuria-Detect (CPT 0365U) as a diagnostic aid, Oncuria-Monitor (CPT 0366U) for recurrence surveillance, and Oncuria-Predict (CPT 0367U) for BCG therapy response prediction. Pipeline additions include Nexus-Dx (neoadjuvant chemotherapy response) and FibraChek (non-invasive liver fibrosis), the latter licensed from Human Metabolomics Institute in August 2023.

Nonagen commercializes Oncuria as a laboratory-developed test (LDT) processed exclusively in its own lab, generating per-test transaction revenue from ordering healthcare providers. The company secured CMS Medicare payment rates for all three variants effective January 1, 2024, and dedicated CPT PLA codes effective January 1, 2023, establishing reimbursement infrastructure. Commercial scaling is executed through a multiyear, multimillion-dollar agreement with Peregrine Market Access as contract commercialization organization, complemented by direct laboratory services and an exclusive manufacturing partnership with Bio-Techne's R&D Systems unit. International revenue potential exists via the June 2022 CE marking for the European market, and future revenue may be supplemented by the HMI-licensed liver fibrosis franchise.

Short descriptiontext

Nonagen Bioscience is a clinical-stage diagnostics company that develops the Oncuria multiplex protein immunoassay for bladder cancer detection, monitoring, and BCG therapy response prediction, serving urologists and clinics through its CLIA-certified laboratory and contract commercialization partner.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersIrvine, United States
HQ citystring
Irvine
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bladder cancer diagnostics, multiplex protein immunoassay, urine biomarker testing, clinical laboratory diagnostics, urology diagnostic tests
Industry5 codes
PRIMARYHLAHAAAG
Urinalysis & Routine Screening Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAKAJ
Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAFAMAB
Clinical Chemistry & Immunoassay Laboratories
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code4 codes
  • Medical and Diagnostic Laboratories62151
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Cancer Diagnostic Tests
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Laboratory Diagnostic Testing (LDT)
TypeTransaction Fee
Description

Nonagen offers Oncuria as a laboratory-developed test (LDT) processed in their own CLIA-certified clinical laboratory. Healthcare professionals order the test, collect urine specimens, and ship to Nonagen's lab for processing. Results are reported to the ordering provider. The company has received Medicare payment rates established by CMS effective January 1, 2024 for Oncuria-Detect, Oncuria-Monitor, and Oncuria-Predict tests. CPT Proprietary Laboratory Analyses (PLA) codes have been assigned: Oncuria-Detect 0365U, Oncuria-Monitor 0366U, and Oncuria-Predict 0367U.

nonagen.com
2Licensing Royalties (Liver Fibrosis Test)
TypeLicensing Royalties
Description

Through an exclusive licensing agreement with Human Metabolomics Institute, Inc. (HMI), Nonagen has rights to develop and commercialize HMI's liver fibrosis/cancer detection technology in the US market and select countries abroad. This represents a potential future revenue stream through licensing arrangements.

nonagen.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details3 tiers
1Oncuria-Detect (0365U) - Bladder cancer diagnosis aid
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Medicare payment rate established effective January 1, 2024. Available for qualified healthcare professionals evaluating patients with hematuria or upper urinary tract abnormalities.

nonagen.com
2Oncuria-Monitor (0366U) - Bladder cancer recurrence monitoring
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Medicare payment rate established effective January 1, 2024. For patients with history of bladder cancer being monitored for tumor recurrence.

nonagen.com
3Oncuria-Predict (0367U) - BCG therapy response prediction
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Medicare payment rate established effective January 1, 2024. For patients with non-muscle invasive bladder cancer being considered for intravesical BCG therapy.

nonagen.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Oncuria
Description

First-of-its-kind multiplex protein immunoassay for bladder cancer detection, monitoring, and prediction of BCG therapy response. Includes Oncuria-Detect, Oncuria-Monitor, and Oncuria-Predict variants.

nonagen.com
+2 more records
Core offering1 text field

Nonagen Bioscience develops and commercializes the Oncuria suite of urine-based multiplex protein immunoassay tests for bladder cancer detection, monitoring, and BCG therapy response prediction. The company operates its own CLIA-certified, CAP-accredited clinical laboratory in Irvine, California where it processes urine specimens sent by healthcare professionals and reports quantitative diagnostic results. The proprietary test measures 10 protein biomarkers combined into a single risk score using Luminex xMAP technology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 93% sensitivity and 93% specificity for detecting bladder cancer in clinical studies
+4 more records
Product overview1 text field

Nonagen Bioscience offers the Oncuria suite of urine-based multiplex immunoassay tests for bladder cancer. The core Oncuria platform detects 10 protein biomarkers (APOE, A1AT, ANG, CA9, IL8, MMP9, MMP10, PAI1, SDC1, VEGF) using Luminex xMAP technology. The platform comprises three distinct sub-products: Oncuria-Detect (aids in diagnosis for patients with hematuria), Oncuria-Monitor (monitors for tumor recurrence in patients with bladder cancer history), and Oncuria-Predict (predicts BCG therapy response). The tests use proprietary multivariate classifier algorithms within a HIPAA-compliant cloud-based system. Additionally, the company is developing pipeline products including Nexus-Dx for chemotherapy response prediction and FibraChek for liver fibrosis assessment.

Product and service3 records
1Oncuria-Detect
CategoryUrology diagnostic test
Description

In vitro multiplex immunoassay for the quantitative detection of 10 bladder cancer-associated proteins in urine. Intended as an aid in evaluating patients with hematuria or upper urinary tract abnormalities for the presence of urothelial cancer, used in conjunction with cystoscopy. Processed as a laboratory-developed test in Nonagen's CLIA-certified laboratory.

2Oncuria-Monitor
CategoryUrology diagnostic test
Description

In vitro multiplex immunoassay for monitoring tumor recurrence in patients previously diagnosed with bladder cancer, used in conjunction with cystoscopy. Detects the same 10 bladder cancer-associated protein biomarkers and is processed as a laboratory-developed test in Nonagen's CLIA-certified laboratory.

3Oncuria-Predict
CategoryUrology diagnostic test
Description

In vitro multiplex immunoassay for predicting rapid failure (recurrence or persistence) in patients with non-muscle invasive bladder cancer who have had tumor transurethral resection and are beginning intravesical BCG therapy. Uses proprietary multivariate algorithms to assess BCG response. Processed as a laboratory-developed test in Nonagen's CLIA-certified laboratory.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2024-10-28
Description

CEO Dr. Charles Rosser was invited to present at Luminex's prestigious xMAP Conference in Houston, TX. Presentation covered the genesis and current state of Oncuria tests designed to revolutionize early detection and management of bladder cancer using xMAP technology platform.

2Human Metabolomics Institute, Inc. (HMI)
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-08-14
Description

Exclusive licensing agreement for HMI's liver fibrosis/cancer detection technology. Nonagen will seek clinical partners to enable widespread healthcare provider access to a noninvasive liver fibrosis detection test throughout the United States and select countries abroad. With liver disease incidence increasing 50% (NAFLD) and 200% (hepatitis C) over past 2 decades, liver fibrosis is a major unmet clinical need.

nonagen.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-05
Description

Successful completion of validation study of Oncuria as a laboratory developed test (LDT). DiaCarta received patient urine samples for testing in its CLIA certified lab in Pleasanton, California. Oncuria demonstrated 93% sensitivity and 93% specificity for detecting bladder cancer with consistent performance across tumor grades and stages.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-05-12
Description

Exclusive supply agreement for R&D Systems, a Bio-Techne brand, to manufacture Nonagen's Oncuria bladder cancer diagnostic panel using xMAP Luminex technology. Bio-Techne provides high-quality reagents and over 40 years of immunoassay experience combined with Nonagen's diagnostic expertise to create a multiplex protein-based urine test for early detection, therapy choice, and disease monitoring of bladder cancer.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2022-01-28
Description

Multiyear, multimillion dollar agreement for Peregrine Market Access to serve as contract commercialization organization and lead the United States launch of Oncuria. Peregrine's team has experience and expertise navigating novel device launch complexities in the United States with shared passion for improving lives of people with chronic, life-threatening conditions.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Liquid biopsy company offering blood-based cancer diagnostics including Guardant360 for oncology treatment selection. Comparable business model (LDT-processed molecular diagnostics with Medicare reimbursement) and broader oncology footprint, though different specimen type (blood vs. urine) and clinical use cases.

TypeDirect peer
Description

Offers Decipher Bladder, a genomic test for bladder cancer treatment decision support. Comparable as a molecular diagnostics company serving urology practices with LDT-processed cancer tests, though using tissue-based rather than urine-based methodology.

TypeDirect peer
Description

Direct competitor in urologic cancer diagnostics with SelectMDx, AssureMDx, and Navigator urine-based tests for prostate and bladder cancer detection. Comparable in clinical workflow (urine biomarker tests for urologists), LDT business model, and European/US commercial footprint.

TypeBroad incumbent
Description

Commercial-stage diagnostics company offering Signatera (tumor-informed MRD test) and other oncology and urology-focused tests. Comparable in LDT business model, direct-to-provider sales motion, and pursuit of Medicare reimbursement, with broader indication portfolio and larger commercial organization.

TypeBroad incumbent
Description

Roche subsidiary offering comprehensive genomic profiling tests (FoundationOne CDx, FoundationOne Liquid CDx) for oncology treatment selection. Comparable as an FDA-approved/CLIA-certified oncology diagnostics laboratory serving urology and oncology practices, with significantly broader test menu and global scale.

TypeOthers
Description

Exclusive manufacturing partner for Oncuria via the R&D Systems brand, supplying reagents and immunoassay expertise. While not a direct competitor, Bio-Techne's ProteinSimple and ExoDx franchises overlap adjacently in the protein biomarker diagnostics space and they have an intimate view of Nonagen's commercial trajectory.

TypeBroad incumbent
Description

Commercial-stage cancer diagnostics company with Cologuard (stool-based colorectal cancer screening) and Oncotype products. Highly comparable business model: LDT-processed cancer screening/monitoring test with Medicare reimbursement, direct-to-provider sales motion, and similar regulatory pathway. Significantly larger scale and broader indication portfolio.

TypeDirect peer
Description

Direct competitor offering Bladder EpiCheck, a urine-based molecular test for bladder cancer recurrence surveillance. Competes head-to-head with Oncuria-Monitor in the surveillance use case and shares the non-invasive urine-based LDT commercial model.

TypeBroad incumbent
Description

Operates within Danaher's Diagnostics Platform offering the GeneXpert molecular diagnostic systems used in clinical laboratories globally. Competes in the clinical diagnostics instrument and reagent space that Nonagen's lab customers use; broader portfolio but provides a comparison point for CLIA-certified laboratory operations and instrument-based diagnostic workflows.

TypeDirect peer
Description

Direct competitor offering Cxbladder, a urine-based molecular diagnostic for bladder cancer detection and recurrence monitoring. Closest comparable in product category (urine-based bladder cancer test), clinical use case (hematuria evaluation, surveillance), and commercial model (LDT processed in own lab).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nonagen Bioscience

Cancer Diagnostic Testsnonagen.com

Nonagen Bioscience is a clinical-stage diagnostics company that develops the Oncuria multiplex protein immunoassay for bladder cancer detection, monitoring, and BCG therapy response prediction, serving urologists and clinics through its CLIA-certified laboratory and contract commercialization partner.

What Nonagen Bioscience does

Nonagen Bioscience Corporation is a clinical-stage diagnostics company developing the Oncuria multiplex protein immunoassay platform for bladder cancer detection, recurrence monitoring, and treatment response prediction. The company serves urologists and clinics evaluating patients presenting with hematuria (blood in urine), patients under surveillance for prior bladder cancer, and patients with non-muscle invasive bladder cancer being considered for BCG therapy. Headquartered in Irvine, California, Nonagen operates its own CAP-accredited, CLIA-certified clinical laboratory (CLIA 05D2051927, CAP 8862074) where it processes specimens shipped from healthcare providers, supported by California and Rhode Island state certifications.

The Oncuria platform is built on xMAP Luminex multiplex bead-based immunoassay technology, quantifying 10 proprietary protein biomarkers (APOE, A1AT, ANG, CA9, IL8, MMP9, MMP10, PAI1, SDC1, and VEGF) from a single voided urine sample using as little as 150 microliters in under 5 hours. A proprietary multivariate classifier algorithm combines biomarker concentrations and clinical inputs into a single risk score delivered via HIPAA-compliant cloud infrastructure. The marketed suite includes Oncuria-Detect (CPT 0365U) as a diagnostic aid, Oncuria-Monitor (CPT 0366U) for recurrence surveillance, and Oncuria-Predict (CPT 0367U) for BCG therapy response prediction. Pipeline additions include Nexus-Dx (neoadjuvant chemotherapy response) and FibraChek (non-invasive liver fibrosis), the latter licensed from Human Metabolomics Institute in August 2023.

Nonagen commercializes Oncuria as a laboratory-developed test (LDT) processed exclusively in its own lab, generating per-test transaction revenue from ordering healthcare providers. The company secured CMS Medicare payment rates for all three variants effective January 1, 2024, and dedicated CPT PLA codes effective January 1, 2023, establishing reimbursement infrastructure. Commercial scaling is executed through a multiyear, multimillion-dollar agreement with Peregrine Market Access as contract commercialization organization, complemented by direct laboratory services and an exclusive manufacturing partnership with Bio-Techne's R&D Systems unit. International revenue potential exists via the June 2022 CE marking for the European market, and future revenue may be supplemented by the HMI-licensed liver fibrosis franchise.

Nonagen Bioscience firmographics

Firmographics
Name
Nonagen Bioscience
Legal name
Nonagen Bioscience Corporation
Website
https://nonagen.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Short description
Nonagen Bioscience is a clinical-stage diagnostics company that develops the Oncuria multiplex protein immunoassay for bladder cancer detection, monitoring, and BCG therapy response prediction, serving urologists and clinics through its CLIA-certified laboratory and contract commercialization partner.
Ownership category
akta.pro rank

Nonagen Bioscience industry classification

Industry
Product category
Cancer Diagnostic Tests
NAICS
Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAHAAAG
Urinalysis & Routine Screening Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAKAJ
Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAFAMAB
Clinical Chemistry & Immunoassay Laboratories
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Bladder cancer diagnostics
  • Multiplex protein immunoassay
  • Urine biomarker testing
  • Clinical laboratory diagnostics
  • Urology diagnostic tests

Where Nonagen Bioscience is headquartered

Location

Headquarters

HQ city
Irvine
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Nonagen Bioscience business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Laboratory Diagnostic Testing (LDT): Nonagen offers Oncuria as a laboratory-developed test (LDT) processed in their own CLIA-certified clinical laboratory. Healthcare professionals order the test, collect urine specimens, and ship to Nonagen's lab for processing. Results are reported to the ordering provider. The company has received Medicare payment rates established by CMS effective January 1, 2024 for Oncuria-Detect, Oncuria-Monitor, and Oncuria-Predict tests. CPT Proprietary Laboratory Analyses (PLA) codes have been assigned: Oncuria-Detect 0365U, Oncuria-Monitor 0366U, and Oncuria-Predict 0367U.
  2. Licensing Royalties (Liver Fibrosis Test): Through an exclusive licensing agreement with Human Metabolomics Institute, Inc. (HMI), Nonagen has rights to develop and commercialize HMI's liver fibrosis/cancer detection technology in the US market and select countries abroad. This represents a potential future revenue stream through licensing arrangements.

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePay-as-you-goOncuria-Detect (0365U) - Bladder cancer diagnosis aid
Transaction based/ take ratePay-as-you-goOncuria-Monitor (0366U) - Bladder cancer recurrence monitoring
Transaction based/ take ratePay-as-you-goOncuria-Predict (0367U) - BCG therapy response prediction

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Nonagen Bioscience product offering

Product offering

Core offering

Nonagen Bioscience develops and commercializes the Oncuria suite of urine-based multiplex protein immunoassay tests for bladder cancer detection, monitoring, and BCG therapy response prediction. The company operates its own CLIA-certified, CAP-accredited clinical laboratory in Irvine, California where it processes urine specimens sent by healthcare professionals and reports quantitative diagnostic results. The proprietary test measures 10 protein biomarkers combined into a single risk score using Luminex xMAP technology.

Product overview

Nonagen Bioscience offers the Oncuria suite of urine-based multiplex immunoassay tests for bladder cancer. The core Oncuria platform detects 10 protein biomarkers (APOE, A1AT, ANG, CA9, IL8, MMP9, MMP10, PAI1, SDC1, VEGF) using Luminex xMAP technology. The platform comprises three distinct sub-products: Oncuria-Detect (aids in diagnosis for patients with hematuria), Oncuria-Monitor (monitors for tumor recurrence in patients with bladder cancer history), and Oncuria-Predict (predicts BCG therapy response). The tests use proprietary multivariate classifier algorithms within a HIPAA-compliant cloud-based system. Additionally, the company is developing pipeline products including Nexus-Dx for chemotherapy response prediction and FibraChek for liver fibrosis assessment.

Differentiator

Problem solved

Functional benefit

Brands

  • Oncuria: First-of-its-kind multiplex protein immunoassay for bladder cancer detection, monitoring, and prediction of BCG therapy response. Includes Oncuria-Detect, Oncuria-Monitor, and Oncuria-Predict variants.
  • Nexus-Dx
  • FibraChek

Products and services

  • Oncuria-Detect In vitro multiplex immunoassay for the quantitative detection of 10 bladder cancer-associated proteins in urine. Intended as an aid in evaluating patients with hematuria or upper urinary tract abnormalities for the presence of urothelial cancer, used in conjunction with cystoscopy. Processed as a laboratory-developed test in Nonagen's CLIA-certified laboratory.
  • Oncuria-Monitor In vitro multiplex immunoassay for monitoring tumor recurrence in patients previously diagnosed with bladder cancer, used in conjunction with cystoscopy. Detects the same 10 bladder cancer-associated protein biomarkers and is processed as a laboratory-developed test in Nonagen's CLIA-certified laboratory.
  • Oncuria-Predict In vitro multiplex immunoassay for predicting rapid failure (recurrence or persistence) in patients with non-muscle invasive bladder cancer who have had tumor transurethral resection and are beginning intravesical BCG therapy. Uses proprietary multivariate algorithms to assess BCG response. Processed as a laboratory-developed test in Nonagen's CLIA-certified laboratory.

Quantifiable outcome

  • 93% sensitivity and 93% specificity for detecting bladder cancer in clinical studies
  • +4 more outcomes

Companies that use Nonagen Bioscience

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Nonagen Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Nonagen Bioscience partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • Luminex CorporationminorGTM or Marketing Partner · 28 October 2024CEO Dr. Charles Rosser was invited to present at Luminex's prestigious xMAP Conference in Houston, TX. Presentation covered the genesis and current state of Oncuria tests designed to revolutionize early detection and management of bladder cancer using xMAP technology platform.
  • Human Metabolomics Institute, Inc. (HMI)minorOEM/ Whitelabel/ Licensing Partner · 14 August 2023Exclusive licensing agreement for HMI's liver fibrosis/cancer detection technology. Nonagen will seek clinical partners to enable widespread healthcare provider access to a noninvasive liver fibrosis detection test throughout the United States and select countries abroad. With liver disease incidence increasing 50% (NAFLD) and 200% (hepatitis C) over past 2 decades, liver fibrosis is a major unmet clinical need.
  • DiaCartacoreStrategic or Co-development Partner · 5 January 2023Successful completion of validation study of Oncuria as a laboratory developed test (LDT). DiaCarta received patient urine samples for testing in its CLIA certified lab in Pleasanton, California. Oncuria demonstrated 93% sensitivity and 93% specificity for detecting bladder cancer with consistent performance across tumor grades and stages.
  • Bio-Techne Corporation (R&D Systems brand)coreTechnology or Integration · 12 May 2022Exclusive supply agreement for R&D Systems, a Bio-Techne brand, to manufacture Nonagen's Oncuria bladder cancer diagnostic panel using xMAP Luminex technology. Bio-Techne provides high-quality reagents and over 40 years of immunoassay experience combined with Nonagen's diagnostic expertise to create a multiplex protein-based urine test for early detection, therapy choice, and disease monitoring of bladder cancer.
  • Peregrine Market AccesscoreGTM or Marketing Partner · 28 January 2022Multiyear, multimillion dollar agreement for Peregrine Market Access to serve as contract commercialization organization and lead the United States launch of Oncuria. Peregrine's team has experience and expertise navigating novel device launch complexities in the United States with shared passion for improving lives of people with chronic, life-threatening conditions.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Nonagen Bioscience competitors and assessment

Company assessment

Broad incumbents

  • Guardant Health: Liquid biopsy company offering blood-based cancer diagnostics including Guardant360 for oncology treatment selection. Comparable business model (LDT-processed molecular diagnostics with Medicare reimbursement) and broader oncology footprint, though different specimen type (blood vs. urine) and clinical use cases.
  • Natera: Commercial-stage diagnostics company offering Signatera (tumor-informed MRD test) and other oncology and urology-focused tests. Comparable in LDT business model, direct-to-provider sales motion, and pursuit of Medicare reimbursement, with broader indication portfolio and larger commercial organization.
  • Foundation Medicine (Roche): Roche subsidiary offering comprehensive genomic profiling tests (FoundationOne CDx, FoundationOne Liquid CDx) for oncology treatment selection. Comparable as an FDA-approved/CLIA-certified oncology diagnostics laboratory serving urology and oncology practices, with significantly broader test menu and global scale.
  • Exact Sciences: Commercial-stage cancer diagnostics company with Cologuard (stool-based colorectal cancer screening) and Oncotype products. Highly comparable business model: LDT-processed cancer screening/monitoring test with Medicare reimbursement, direct-to-provider sales motion, and similar regulatory pathway. Significantly larger scale and broader indication portfolio.
  • Cepheid (Danaher): Operates within Danaher's Diagnostics Platform offering the GeneXpert molecular diagnostic systems used in clinical laboratories globally. Competes in the clinical diagnostics instrument and reagent space that Nonagen's lab customers use; broader portfolio but provides a comparison point for CLIA-certified laboratory operations and instrument-based diagnostic workflows.

Direct peers

  • Veracyte: Offers Decipher Bladder, a genomic test for bladder cancer treatment decision support. Comparable as a molecular diagnostics company serving urology practices with LDT-processed cancer tests, though using tissue-based rather than urine-based methodology.
  • MDxHealth: Direct competitor in urologic cancer diagnostics with SelectMDx, AssureMDx, and Navigator urine-based tests for prostate and bladder cancer detection. Comparable in clinical workflow (urine biomarker tests for urologists), LDT business model, and European/US commercial footprint.
  • Nucleix: Direct competitor offering Bladder EpiCheck, a urine-based molecular test for bladder cancer recurrence surveillance. Competes head-to-head with Oncuria-Monitor in the surveillance use case and shares the non-invasive urine-based LDT commercial model.
  • Pacific Edge Diagnostics: Direct competitor offering Cxbladder, a urine-based molecular diagnostic for bladder cancer detection and recurrence monitoring. Closest comparable in product category (urine-based bladder cancer test), clinical use case (hematuria evaluation, surveillance), and commercial model (LDT processed in own lab).

Others

  • Bio-Techne: Exclusive manufacturing partner for Oncuria via the R&D Systems brand, supplying reagents and immunoassay expertise. While not a direct competitor, Bio-Techne's ProteinSimple and ExoDx franchises overlap adjacently in the protein biomarker diagnostics space and they have an intimate view of Nonagen's commercial trajectory.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Nonagen Bioscience social profiles

Digital presence

Nonagen Bioscience compliance and trust

Trust signal

Compliance4 records

Nonagen Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nonagen Bioscience leadership team

Management profile

Number of profiles

Profiles11 records

Nonagen Bioscience funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nonagen Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nonagen Bioscience

What does Nonagen Bioscience do?

Nonagen Bioscience develops and commercializes the Oncuria suite of urine-based multiplex protein immunoassay tests for bladder cancer detection, monitoring, and BCG therapy response prediction. The company operates its own CLIA-certified, CAP-accredited clinical laboratory in Irvine, California where it processes urine specimens sent by healthcare professionals and reports quantitative diagnostic results. The proprietary test measures 10 protein biomarkers combined into a single risk score using Luminex xMAP technology.

Is Nonagen Bioscience a public or private company?

Nonagen Bioscience is a private company. It is classified as unknown and is currently operating.

When was Nonagen Bioscience founded?

Nonagen Bioscience was founded in 2011. It employs 1 to 10 people.

Where is Nonagen Bioscience based?

Nonagen Bioscience is headquartered in Irvine, United States, in the North America region.

How does Nonagen Bioscience make money?

Two revenue lines are on record. Laboratory Diagnostic Testing (LDT) is the primary driver. The others are licensing Royalties (Liver Fibrosis Test).

Who are Nonagen Bioscience's main competitors?

Broad incumbents on record are Guardant Health, Natera, Foundation Medicine (Roche), Exact Sciences and Cepheid (Danaher). Direct peers are Veracyte, MDxHealth, Nucleix and Pacific Edge Diagnostics. Bio-Techne is listed as an others.

Does Nonagen Bioscience have an API?

No public API is recorded for Nonagen Bioscience.

What industry is Nonagen Bioscience in?

Nonagen Bioscience's product category is Cancer Diagnostic Tests. Its primary akta.pro industry code is HLAHAAAG, Urinalysis & Routine Screening Diagnostics, with a secondary code of HLAHAKAJ, Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status). Its NAICS code is 62151 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialLumea Enhances Digital Diagnostic Ecosystem With Nonagen Bioscience's Oncuria® Suite Of Bladder Cancer TestsLumea integrated Nonagen Bioscience's Oncuria suite of bladder cancer tests into its digital diagnostics platform. The integration includes three assays—Detect, Monitor, and Predict—designed for detection, surveillance, and treatment response assessment. The partnership aims to streamline ordering and connect clinical information within urologists' workflows.EIN PresswireLumea Enhances Digital Diagnostic Ecosystem with Nonagen Bioscience’s Oncuria® Suite of Bladder Cancer TestsLumea integrated Nonagen Bioscience's Oncuria suite of bladder cancer tests into its digital diagnostics platform, bringing Detect, Monitor, and Predict assays to urologists' workflows. The tests use multiplex urine biomarkers and AI to provide risk assessments, with Detect for new cases, Monitor for surveillance, and Predict for BCG therapy response.EIN PresswireLumea Enhances Digital Diagnostic Ecosystem with Nonagen Bioscience’s Oncuria® Suite of Bladder Cancer TestsLumea integrated Nonagen Bioscience's Oncuria suite of bladder cancer tests into its digital diagnostics platform. The integration includes Detect, Monitor, and Predict assays for bladder cancer detection, surveillance, and treatment response assessment. The partnership aims to streamline ordering and connect clinical information within urologists' workflows.Urology TimesCMS establishes payment rate for Oncuria bladder cancer testsThe Centers for Medicare & Medicaid Services (CMS) established a Medicare payment rate for the Oncuria bladder cancer tests developed by DiaCarta and Nonagen Biosciences, effective January 1, 2024. This coverage decision allows for reimbursement of three specific indications: early detection, recurrence monitoring, and treatment response prediction. The approval marks a significant milestone for the developers, enabling wider adoption of the tests which utilize protein detection in urine samples.PR NewswireNonagen Bioscience announces Timothy "TJ" Johnson as Executive Chair of Nonagen Bioscience CorporationNonagen Bioscience, a cancer diagnostics company headquartered in Los Angeles, has appointed Timothy "TJ" Johnson as Executive Chair of the corporation. Johnson brings nearly 30 years of executive leadership experience in the life sciences industry, including serving as president and CEO of HTG Molecular Diagnostics where he led a successful IPO in 2015. The company is focused on advancing its Oncuria® liquid biopsy test for bladder cancer detection, which is currently seeking US Food and Drug Administration approval.PR NewswireTackling Recurring Health Conditions Offers Hope to PatientsCardiol Therapeutics received its third FDA Investigational New Drug authorization for CardiolRx™ to treat recurrent pericarditis, launching a Phase II open-label pilot study enrolling 25 patients at major US clinical centers. The company also announced parallel development for acute myocarditis and noted eligibility for orphan drug status in two indications, adding potential value. The article additionally covers Merck's EU approval of KEYTRUDA® for triple-negative breast cancer and Bio-Techne's manufacturing agreement with Nonagen Bioscience for a bladder cancer diagnostic panel.BioWorldNonagen lands CE mark for Oncuria bladder cancer testNonagen Bioscience Corp. obtained CE marking for its Oncuria immunoassay for bladder cancer. The multiplex urine test detects 10 proteins and has 93% sensitivity and specificity, and can predict response to BCG therapy.PR NewswireNonagen Bioscience announces CE mark for Oncuria® bladder cancer diagnosticNonagen Bioscience announced CE marking for its Oncuria bladder cancer immunoassay, enabling European sales. The test detects 10 urine biomarkers with 93% sensitivity and specificity. A US launch is planned for the last quarter of 2022, followed by a European IVDD launch pending FDA approval.PR NewswireNonagen Bioscience announces Wayne Hogrefe, PhD as chief operating officer (COO)Nonagen Bioscience announced the appointment of Wayne Hogrefe, PhD as Chief Operating Officer, effective immediately. Dr. Hogrefe brings more than 30 years of diagnostics industry experience and will oversee the launch of the company's lead diagnostic Oncuria as a laboratory developed test for bladder cancer by the end of 2022, while also leading FDA approval efforts for the in vitro diagnostic designation. The Los Angeles-based biotechnology company, founded in 2011, is developing diagnostics for bladder, breast, and prostate cancers.BioSpaceNonagen Bioscience Granted FDA Breakthrough Device DesignationNonagen Bioscience received FDA Breakthrough Device Designation for its Oncuria bladder cancer test, which predicts response to BCG therapy. The test measures 10 protein biomarkers in urine to aid treatment decisions. The designation enables expedited FDA review and formal recognition of clinical benefit.